Month: February 2020

PHOTO RELEASE–National Security Cutter Stone (WMSL 758) Christened at Ingalls Shipbuilding

PASCAGOULA, Miss., Feb. 29, 2020 (GLOBE NEWSWIRE) — Huntington Ingalls Industries’ (NYSE: HII) Ingalls Shipbuilding division christened National Security Cutter Stone (WMSL 758) today. Stone is the ninth Legend-class NSC to be built at Ingalls.The ship honors Coast Guard officer Cmdr. Elmer “Archie” Fowler Stone, who made history in 1919 for being one of the two Coast Guard pilots to successfully make the first transatlantic flight in a Navy seaplane. Stone’s great niece, Laura Cavallo, officially christened the ship.“Today we celebrate the time and talents our shipbuilders have invested in this incredible ship,” Ingalls Shipbuilding President Brian Cuccias said. “The success of the National Security Cutter program is a direct reflection of our strong partnership with the Coast Guard and the dedication and capability of a team of...

Continue reading

Activity results of twelve months of year 2019 of company AB “Linas” Group of companies. AB “Linas” not audited consolidated interim information of twelve months of year 2019

On February 28, 2020 AB “Linas” Board confirmed AB “Linas” consolidated interim financial reports of twelve months of year 2019 which are not checked by the auditors and prepared acc.to International financial accountability standards accepted by EU.The sales incomes for January-December of year 2019 of AB “Linas” Group of companies made 12,98 mln EUR. During the same period of year 2018 sales incomes were 12,71 mln EUR.Profit before taxation of the twelve months of year 2019 of AB “Linas” group of companies – 0.13 mln EUR. Group result for same period of year 2018 – 0.51 mln EUR profit.Presenting confirmation of the responsible persons of AB “Linas” and interim consolidated not audited financial information of twelve months of year 2019.AB “Linas” chief of financeEgidijus Mikeliūnas+370 45 506100AttachmentAtskaitomybė 1912 ENG

Continue reading

AB „Linas“ įmonių Grupės 2019 metų dvylikos mėnesių veiklos rezultatai. AB „Linas“ 2019 metų dvylikos mėnesių neaudituota konsoliduota tarpinė informacija

2020 m. vasario 28 d. AB „Linas“ valdyba patvirtino auditorių netikrintas AB „Linas“ 2019 metų dvylikos mėnesių konsoliduotas tarpines finansines ataskaitas, parengtas pagal ES priimtus Tarptautinius finansinės atskaitomybės standartus.AB „Linas“ Grupės 2019 metų sausio-gruodžio mėnesių pardavimo pajamos sudarė 12,98 mln. eurų, kai 2018 m. tuo pačiu laikotarpiu – 12,71 mln. eurų.AB „Linas“ įmonių grupės 2019 metų dvylikos mėnesių pelnas prieš apmokestinimą – 0,13 mln. eurų. 2018 m. to paties laikotarpio Grupės rezultatas – pelnas 0,51 mln. eurų.Pateikiame AB „Linas“ atsakingų asmenų patvirtinimą ir 2019 m. dvylikos  mėnesių tarpines konsoliduotas neaudituotas finansines ataskaitas.AB „Linas“ finansų vadovasEgidijus Mikeliūnas+370 45 506100PriedasAtskaitomybė 1912 LTU

Continue reading

Dow Jones slumped more than 1,000 points as COVID-19 Outbreak Worldwide

The Dow Jones Industrial Average drops more than 1,000 points due to the virus outbreak begun at Wuhan China. Investors are worry because of the Covid-19 outbreak and according to them; this is the worst day for the stock market in 2 years. It lost 1,031.61 points, or 3.6%, to 27,960.80. At its low point, it was down 1,079 points to be exact. Most investors seek safety in U.S. government bonds, gold and high-dividend stocks like utilities and real estate. The yield on the 10-year Treasury fell to the lowest level in more than 3-years. This is the biggest loss since December 2018. The Nasdaq dropped 355.31 points, or 3.7%, to 9,221.28. The S&P 500 index skidded 111.86 points, or 3.4%, to 3,225.89. While the Russell 2000 index of smaller company stocks gave up 50.50 points, or 3%, to 1,628.10. “Covid-19 (Coronavirus) is a virus affecting...

Continue reading

Sunborn (Gibraltar) Limited Plc: INTERIM REPORT FOR JANUARY – DECEMBER 2019

SUNBORN GIBRALTAR PLC: INTERIM REPORT FOR JANUARY – DECEMBER 2019STOCK EXCHANGE RELEASE February 29th 2020This is a summary of the Q4 2019 interim financial report. The complete report is attached to this release and is also available at www.sunborn.com/press/Key Figures (IFRS) – Issuer Sunborn Gibraltar PlcSunborn Gibraltar Plc Financial summary 1 January – 30 December 2019Sunborn receives lease income from the management company. Lease income was £3.18M in 2019 (£3.18M in 2018). Operating costs were in line with previous year.The value of the Yacht hotel is at €113.6M based on the latest valuation report dated May 2019.Business environmentThe months of November and December experienced a decline in leisure business as expected due to the published Brexit date of 31 October, other than this there were no notable changes in...

Continue reading

Athenex, Inc. 報告截至 2019 年 12 月 31 日的第四季度及年度財務業績,並提供公司的最新動態

用於光化性角化病的 Tirbanibulin 軟膏 NDA 經已提交口服紫杉醇 NDA 提交進展順利;FDA 最終會議定於 4 月初舉行SABCS 的口服紫杉醇的第 3 期結果簡報獲得廣泛好評2019 年產品收入同年比增長 43%,總收入同年比增長 14%美國東部時間今天上午 8:00 進行電話會議和網上廣播紐約州水牛城, Feb. 29, 2020 (GLOBE NEWSWIRE) — Athenex,Inc. (NASDAQ: ATNX) 是一家致力於研究、開發和商業化治療癌症和相關疾病的新型療法的全球生物製藥公司,現已公佈截至 2019 年 12 月 31 日的第四季度財務報表和業務摘要。「在經歷了非常成功和富成效的 2019 年之後,我們團隊的即時焦點是對我們兩個最先進的候選藥物 – 口服紫杉醇和 Tirbanibulin 軟膏進行監管批准。 這兩種產品都有潛質改變各自市場的護理標準。」 Athenex 的行政總裁兼董事長 Dr. Johnson Lau 表示。 「我們一直在製造和商業基礎設施上進行必要的投資,以確保經批准的口服紫杉醇成功上市。我們的目標是將口服紫杉醇建立為轉移性乳腺癌患者接受化療時的治療選擇。」2019 年第四季度及近期業務重點:臨床項目:Tirbanibulin 軟膏用於光化性角化病 (AK)新藥物申請(NDA)已提交給 FDA。口服紫杉醇用於治療轉移性乳腺癌在 2019 年聖安東尼奧乳腺癌研討會(SABCS)上發表的結果顯示,與 IV 紫杉醇相比,口服紫杉醇在轉移性乳腺癌的治療中產生更佳反應和整體生存效益。與靜脈注射紫杉醇相比,口服紫杉醇的神經病變發生率較低。口服紫杉醇摘要已獲 SABCS 的刊載計劃接受。FDA 的最終會議定於 4 月初舉行,公司計劃在此之後將在美國提交一份 NDA。企業公佈:通過在中國、香港和澳門地區獲得口服紫杉醇、口服 Irinotecan 和 tirbanibulin 軟膏的許可協議,擴大與廣州香雪藥業的策略合作夥伴關係。Athenex...

Continue reading

Euro Manganese annonce les résultats de l’assemblée générale annuelle et extraordinaire ainsi que le plan de succession du président

VANCOUVER, Colombie-Britannique, 29 févr. 2020 (GLOBE NEWSWIRE) — Euro Manganese Inc. (TSX-V/ASX : EMN) (la « Société » ou «  EMN ») a le plaisir d’annoncer que les actionnaires ont voté en faveur de tous les points présentés lors de l’Assemblée générale annuelle et extraordinaire des actionnaires de la Société (l’« Assemblée » ) qui s’est tenue le 27 février 2020.  Les résultats détaillés du vote de l’Assemblée sont présentés ci-dessous. En ce qui concerne l’élection des administrateurs de la Société, les huit administrateurs candidats à la réélection ont été élus par un vote à main levée comme indiqué ci-dessous :Les autres questions à l’ordre du jour de l’Assemblée ont été adoptées comme indiqué ci-dessous :Cette motion a été adoptée et décidée par un vote à main levée.Cette motion...

Continue reading

Euro Manganese gibt Ergebnisse der Jahreshauptversammlung und außerordentlichen Sitzung sowie die Nachfolgeplanung für den Vorsitz bekannt

VANCOUVER, British Columbia, Feb. 29, 2020 (GLOBE NEWSWIRE) — Euro Manganese Inc. (TSX-V/ASX: EMN) (die „Gesellschaft“ oder „EMN“) freut sich, bekannt geben zu können, dass die Aktionäre für alle Geschäftsangelegenheiten gestimmt haben, die ihnen auf der Jahreshauptversammlung und außerordentlichen Sitzung der Aktionäre (die „Versammlung“) am 27. Februar 2020 vorgelegt wurden.  Die Abstimmungsergebnisse der Versammlung sind nachstehend detailliert aufgeführt. Bei der Wahl der Verwaltungsratsmitglieder der Gesellschaft wurden alle acht zur Wiederwahl stehenden Verwaltungsratsmitglieder auf Basis einer Abstimmung durch Handzeichen wie unten aufgeführt gewählt:Weitere Geschäftsangelegenheiten wurden auf der Versammlung wie nachstehend aufgeführt genehmigt:Dieser Beschluss wurde per Abstimmung durch Handzeichen angenommen.Dieser Beschluss...

Continue reading

CENTOGENE Marks Rare Disease Day 2020 With a Global Line up of Events

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 29, 2020 (GLOBE NEWSWIRE) — CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, will be raising awareness and building community for all those affected by rare genetic diseases with simultaneous events in Berlin, Germany, Lahore, Pakistan, and Mexico City, Mexico on Rare Disease Day 2020. CENTOGENE’s Rare Disease Day events will bring together patients, advocacy groups, policy makers, researchers, health professionals, and the wider community – focused on improving the overall knowledge and identifying solutions to the challenges that rare diseases pose to patients and their families.“Rare Disease Day is extremely...

Continue reading

Monument Reports Second Quarter Fiscal 2020 Results

VANCOUVER, British Columbia, Feb. 28, 2020 (GLOBE NEWSWIRE) — Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its second quarter production and financial results for the three months ended December 31, 2019. All amounts are in United States dollars unless otherwise indicated (refer to www.sedar.com for full financial results).President and CEO Cathy Zhai commented on second quarter fiscal 2020 financial results: “Our second quarter production was in line with last year’s same quarter, it has brought total year to date production to 9,679 ounce of gold higher than 7,961 ounces of gold in the same period of the last fiscal year. Additionally, the Peranggih area continues to be a target for mining pending results of bulk sample test work. Haul road construction was primarily completed...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.